Pharmaceutical Research & Development | AbbVie
AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives
Patient Assistance | AbbVie
Oct 24, 2024 · AbbVie is committed to helping patients get the medicines they need. That’s why we offer patient assistance programs that provide free AbbVie medicines to qualifying patients.
AbbVie Inc. (ABBV) Stock Price, News, Quote & History - Yahoo Finance
Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing.
Products | AbbVie
AbbVie discovers and delivers innovative medicines and solutions that enhance people’s lives.
AbbVie - Wikipedia
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, [2] and rank 89 on the 2024 list. [3]
AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?
3 days ago · The drug, picked up in AbbVie's $8.7 billion acquisition of Cerevel Therapeutics, failed to ease symptoms like hallucinations and delusions, leading the company to book a staggering $3.5 billion ...
AbbVie CEO says psychiatric drug space challenging, more …
3 days ago · AbbVie plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on Wednesday, months after its experimental ...
Investor Overview | AbbVie
AbbVie discovers, develops, and commercializes advanced therapies that have an impact on people's lives. Today, our passionate AbbVie team has approximately ~50,000 employees working together to help patients around the world.
AbbVie's Quarterly Earnings Preview: What You Need to Know
2 days ago · For the full fiscal 2024, AbbVie is expected to deliver an adjusted EPS of $10.06, down 9.5% from $11.11 in fiscal 2023.While in fiscal 2025, its earnings are expected to rebound 21.6% year-over ...
AbbVie to Post $3.5 Billion Impairment Charge on Failed Cerevel …
Jan 10, 2025 · AbbVie on Friday said it will post a $3.5 billion impairment charge related to last year's $8.7 billion bet on Cerevel Therapeutics following the failure of the deal's key drug candidate. AbbVie ...